fda tirzepatide decision URGENT UPDATE: Facing Major Blow in Compounded Trial – Coming SOON! FDA ban on compounded tirzepatide:

Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: a network meta-analysis of large randomized trials

Its less about your biological age and more about extending healthspanthe number of years you feel strong, mobile, and metabolically healthy

GLP-1 medications which include liraglutide and semaglutide also target the incretin hormones and are effective for the treatment of diabetes and weight loss

Potential long-term risks: Chronic use can lead to cardiac complications and certain neurological effects

In patients taking semaglutide alone, the risk of hypoglycemia is relatively low (0-3.8%)

447 Platelets and fibrosis Fibrosis is caused by an imbalance in the repair response of wounds and connective tissue, leading to excessive deposition of extracellular matrix